Navigation Links
Debiopharm Announces U.S. NDA Filing of Trelstar(R) 6-Month Formulation for Locally Advanced or Metastatic Prostate Cancer
Date:11/13/2008

LAUSANNE, Switzerland, Nov. 13 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist focusing on serious medical conditions and particularly oncology, today announced that the New Drug Application (NDA) for the 6 month formulation of Trelstar(R) (triptorelin pamoate) has been accepted for filing by the United States (U.S.) Food and Drug Administration (FDA). Trelstar(R) is a luteinizing hormone releasing hormone (LHRH) agonist for the treatment of locally advanced or metastatic prostate cancer. Once approved, Trelstar(R) will be commercialised in the U.S. by Watson Pharmaceuticals, Inc.

"Last September we announced the filing of the product with the European Agencies, under the name Decapeptyl(R). We are proud to have accomplished the simultaneous filings of Trelstar(R) and Decapeptyl(R) in both the U.S. and Europe, it's a great achievement for us," said Rolland-Yves Mauvernay, president and founder of Debiopharm Group. "This demonstrates our ability to work effectively not only with different regulatory agencies, but also different partners. Furthermore, our FDA inspected research development and production facility, Debio R.P., will produce both products for global distribution."

The NDA for the 6 month formulation of Trelstar(R) is supported by data from a phase III study on the efficacy and safety of two consecutive injections of triptorelin 6-month formulation in 120 patients with advanced prostate cancer. The results showed that 97.5% of patients achieved castrate levels of serum testosterone 28 days after the first injection and that 93% of the patients maintained serum testosterone levels below castrate level (defined as < 1.735 nmol/L or 50 ng/dL) from week 8 to 48. These efficacy results are similar to those obtained previously with repeated administrations of the 1- and 3-month formulations of Trelstar(R), which are already marketed by Watson Pharmaceuticals, Inc.

About Debiopharm Group

Debiopharm Group is a global biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. Debiopharm develops its products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing.

Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed three products with global combined sales in excess of $2.65 billion in 2007.

For more information on Debiopharm Group, please visit: http://www.debiopharm.com

Debiopharm S.A. Contacts Additional Media Contacts

In London

Maurice Wagner Maitland

Director Corporate Affairs & Brian Hudspith

Communications Tel: +44 (0)20 7379 5151

Tel.: +41 (0)21 321 01 11 bhudspith@maitland.co.uk

Fax : +41 (0)21 321 01 69

mwagner@debiopharm.com

Jo-Anne Lutjens In New York

Communications Manager Russo Partners, LLC

Tel.: +41 (0)79 370 27 15 Wendy Lau

Fax: +41 (0)21 321 01 69 Tel: +1 212-845-4272

jalutjens@debiopharm.com Fax: +1 212-845-4260

wendy.lau@russopartnersllc.com


'/>"/>
SOURCE Debiopharm Group
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Debiopharm and NanoCarrier Sign License and Supply Agreement for Dach-Platin Polymeric Micelle in Oncology
2. Ipsen and Debiopharm Extend Their Agreement for the Exclusive Commercialization of Decapeptyl(R) (triptorelin pamoate) in Europe and Certain Other Territories
3. In a Down Economy, Womens Health Company Announces Growth
4. R&Q Solutions, LLC Announces Launch to Serve Regions Medical Device Industry
5. WellPoint Announces Second Annual Innovation Event
6. CVS Caremark All Kids Can Announces the Opening of a Boundless Playground in Los Angeles to Serve Children of All Abilities
7. Sentry Data Systems Announces Healthcare Business Intelligence Technology Platform
8. HealthCentral Announces New Condition-Specific Ad Service to Offer Marketers the Highest Qualified Audiences
9. Wound Management Technologies, Inc. Announces FDA Clearance of 510k
10. GLEH LA, a Nonprofit Affiliate of Gay & Lesbian Elder Housing, Announces New Program Director
11. Governor Rendell Announces the Passing of Lt. Gov. Catherine Baker Knoll
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... , ... The Visiting Nurse Association (VNA) of Somerset Hills is proud to ... unique items from across the nation, this holiday-themed event will raise funds and awareness ... VNA. The boutique will be open Saturday, November 4 (10:00 a.m. – 5:00 ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented ... the lowdown on sciatica in a new episode of "Success Files," which is ... events and innovation and investigates each subject in-depth with passion and integrity. , ...
(Date:10/12/2017)... ... October 12, 2017 , ... First ... compliance program management, will showcase a range of technology and learning solutions at ... (NCAL) Convention and Expo to be held October 14–18, 2017 at the Mandalay ...
(Date:10/12/2017)... ... 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of ... innovative new design of the shoulder pad. The shoulder pad provides optimal support ... your pain while using cold therapy. By utilizing ice and water that is circulated ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, ... a medical article to the newly revamped Cosmetic Town journal section, ... hair transplant procedure known as Follicular Unit Extraction (FUE). , Dr. ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)...  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today provided ... Piedras, Puerto Rico , where the ... Following a comprehensive onsite ... structural damage, temporary loss of power and minimal water ... manufacturing operations have resumed, and the company expects to ...
(Date:10/4/2017)...  South Korean-based healthcare product Development Company I.M. Lab ... Kickstarter. The device will educate the user about ,proper, ... efficiency compared to the dated and pricey CPR training ... of the compression for a more informed CPR training. ... raise $5,000. cprCUBE ...
(Date:10/2/2017)... 2, 2017  AllianceRx Walgreens Prime, the combined central ... and pharmacy benefit manager Prime Therapeutics LLC (Prime), today ... included the unveiling of new signage at its headquarters ... as at a few other company-owned facilities across the ... patients, some of whom will begin to see the ...
Breaking Medicine Technology: